CSPC Strikes US$1.2 Billion AstraZeneca Deal for Long-Acting Peptide and Obesity Drugs

CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an update.

CSPC Pharmaceutical Group has entered into a strategic collaboration and license agreement with AstraZeneca to co-develop innovative long-acting peptide medicines using CSPC’s sustained-release delivery and AI peptide discovery platforms. Under the deal, CSPC will continue advancing its existing preclinical long-acting peptide pipeline, discover and develop additional long-acting peptide products for AstraZeneca, and license AstraZeneca exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to its once-monthly injectable weight-management portfolio, including SYH2082 and three preclinical obesity-related programmes, plus four new collaborative programmes. In return, CSPC will receive an upfront payment of US$1.2 billion, be eligible for up to US$3.5 billion in R&D milestones and up to US$13.8 billion in sales milestones, along with up to double-digit royalties on net sales, significantly strengthening its financial resources while positioning the company as a key regional partner in the fast-growing global market for long-acting obesity and weight-management drugs.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company that develops and manufactures innovative medicines, with a growing focus on long-acting peptide therapies supported by its proprietary sustained-release delivery and AI-driven peptide drug discovery platforms. The group targets chronic and long-term treatment areas where improved dosing convenience and patient adherence can deliver competitive advantages and address significant unmet medical needs.

Average Trading Volume: 116,550,788

Technical Sentiment Signal: Buy

Current Market Cap: HK$114.3B

For detailed information about 1093 stock, go to TipRanks’ Stock Analysis page.